Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease.
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
20
12
2018
accepted:
22
07
2019
revised:
27
08
2019
pubmed:
16
8
2019
medline:
8
1
2020
entrez:
16
8
2019
Statut:
epublish
Résumé
Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. NF is safe and effective for paediatric and adult Chagas disease. We evaluated the degree of NF transfer into breast milk in lactating women with Chagas disease. Prospective study of a cohort of lactating women with Chagas disease. Patients were treated with NF for 1 month. NF was measured in plasma and milk by high performance liquid chromatography (HPLC). Breastfed infants were evaluated at admission, 7th and 30th day of treatment (and monthly thereafter, for 6 months). Lactating women with chronic Chagas disease (N = 10) were enrolled (median age 28 years, range 17-36). Median NF dose was 9.75 mg/kg/day three times a day (TID). Six mothers had mild adverse drug reactions (ADRs), but no ADRs were observed in any of the breastfed infants. No interruption of breastfeeding was observed. Median NF concentrations were 2.15 mg/L (Inter quartil range (IQR) 1.32-4.55) in milk and 0.30 mg/L (IQR 0.20-0.95) in plasma. Median NF milk/plasma ratio was 16 (range 8.75-30.25). Median relative infant NF dose (assuming a daily breastmilk intake of 150 mL/kg/day) was 6.7% of the maternal dose/kg/day (IQR 2.35-7.19%). The low concentrations of NF in breast milk and the normal clinical evaluation of the breastfed babies imply that maternal NF treatment for Chagas disease during breastfeeding is unlikely to lead to clinically relevant exposures in the breastfed infants. Clinical trial registry name and registration number: ClinicalTrials.gov NCT01744405.
Sections du résumé
BACKGROUND
Treatment with nifurtimox (NF) for Chagas disease is discouraged during breast-feeding because no information on NF transfer into breast milk is available. NF is safe and effective for paediatric and adult Chagas disease. We evaluated the degree of NF transfer into breast milk in lactating women with Chagas disease.
PATIENTS AND METHODS
Prospective study of a cohort of lactating women with Chagas disease. Patients were treated with NF for 1 month. NF was measured in plasma and milk by high performance liquid chromatography (HPLC). Breastfed infants were evaluated at admission, 7th and 30th day of treatment (and monthly thereafter, for 6 months).
RESULTS
Lactating women with chronic Chagas disease (N = 10) were enrolled (median age 28 years, range 17-36). Median NF dose was 9.75 mg/kg/day three times a day (TID). Six mothers had mild adverse drug reactions (ADRs), but no ADRs were observed in any of the breastfed infants. No interruption of breastfeeding was observed. Median NF concentrations were 2.15 mg/L (Inter quartil range (IQR) 1.32-4.55) in milk and 0.30 mg/L (IQR 0.20-0.95) in plasma. Median NF milk/plasma ratio was 16 (range 8.75-30.25). Median relative infant NF dose (assuming a daily breastmilk intake of 150 mL/kg/day) was 6.7% of the maternal dose/kg/day (IQR 2.35-7.19%).
CONCLUSIONS
The low concentrations of NF in breast milk and the normal clinical evaluation of the breastfed babies imply that maternal NF treatment for Chagas disease during breastfeeding is unlikely to lead to clinically relevant exposures in the breastfed infants.
TRIAL REGISTRATION
Clinical trial registry name and registration number: ClinicalTrials.gov NCT01744405.
Identifiants
pubmed: 31415566
doi: 10.1371/journal.pntd.0007647
pii: PNTD-D-18-01831
pmc: PMC6711540
doi:
Substances chimiques
Trypanocidal Agents
0
Nifurtimox
M84I3K7C2O
Banques de données
ClinicalTrials.gov
['NCT01744405']
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007647Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pediatrics. 2006 Mar;117(3):e387-95
pubmed: 16510619
Pediatrics. 2013 Sep;132(3):e796-809
pubmed: 23979084
Ther Drug Monit. 2013 Aug;35(4):522-6
pubmed: 23851912
PLoS Negl Trop Dis. 2015 Feb 27;9(2):e0003465
pubmed: 25723465
Expert Rev Anti Infect Ther. 2007 Aug;5(4):717-26
pubmed: 17678432
Talanta. 2013 Mar 30;107:95-102
pubmed: 23598198
Acta Trop. 2010 Jul-Aug;115(1-2):14-21
pubmed: 19932071
Am J Trop Med Hyg. 2015 Dec;93(6):1224-1230
pubmed: 26392162
Am J Trop Med Hyg. 1998 Oct;59(4):526-9
pubmed: 9790423
Clin Infect Dis. 1995 Sep;21(3):551-5
pubmed: 8527542
Mem Inst Oswaldo Cruz. 2007 Oct 30;102 Suppl 1:95-7
pubmed: 17906803
Mem Inst Oswaldo Cruz. 2015 Jun;110(4):507-9
pubmed: 25993401
Clin Infect Dis. 2010 Nov 15;51(10):e69-75
pubmed: 20932171
Mem Inst Oswaldo Cruz. 1988 Jan-Mar;83(1):37-9
pubmed: 3150483
Pediatrics. 2012 Mar;129(3):e827-41
pubmed: 22371471
Lancet. 1996 Nov 23;348(9039):1407-13
pubmed: 8937280
Exp Physiol. 1999 Mar;84(2):435-47
pubmed: 10226183
N Engl J Med. 2000 Jul 13;343(2):118-26
pubmed: 10891521
Clin Pharmacol Ther. 2011 Jun;89(6):830-6
pubmed: 21525869
PLoS Negl Trop Dis. 2009;3(4):e419
pubmed: 19381287
Arch Dis Child. 2015 Jan;100(1):90-4
pubmed: 25210104
PLoS Negl Trop Dis. 2013;7(1):e2000
pubmed: 23350002
Pediatrics. 2011 Jan;127(1):e212-8
pubmed: 21173000
Rev Hosp Clin Fac Med Sao Paulo. 1988 May-Jun;43(3):146-7
pubmed: 3150609
Child Adolesc Psychiatr Clin N Am. 2015 Jan;24(1):1-20
pubmed: 25455573
Arch Dis Child. 2010 Mar;95(3):224-8
pubmed: 19948512
J Clin Lab Anal. 2013 Sep;27(5):384-90
pubmed: 24038224
Ginecol Obstet Mex. 2015 Aug;83(8):487-93
pubmed: 26591033
Pediatr Clin North Am. 2013 Apr;60(2):471-85
pubmed: 23481112
J Obstet Gynaecol Res. 2019 Mar;45(3):522-531
pubmed: 30663176
Pharm Res. 2004 Apr;21(4):555-66
pubmed: 15139511
Mem Inst Oswaldo Cruz. 2007 Oct 30;102 Suppl 1:75-85
pubmed: 17891282
PLoS Negl Trop Dis. 2014 May 22;8(5):e2907
pubmed: 24853169
Ann Intern Med. 2006 May 16;144(10):724-34
pubmed: 16702588
Rev Inst Med Trop Sao Paulo. 2001 May-Jun;43(3):161-2
pubmed: 11452325
N Engl J Med. 2006 Dec 7;355(23):2488-9; author reply 2490-1
pubmed: 17151373
Brain Res. 2012 Feb 3;1436:111-21
pubmed: 22200378
Parasitology. 2013 Feb;140(2):147-59
pubmed: 23010131